• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

使用多参数磁共振成像对管腔B样亚型乳腺癌患者新辅助化疗反应进行早期评估:一项单中心前瞻性研究

Early Assessment of Neoadjuvant Chemotherapy Response Using Multiparametric Magnetic Resonance Imaging in Luminal B-like Subtype of Breast Cancer Patients: A Single-Center Prospective Study.

作者信息

Kovacevic Lucija, Petrovecki Marko, Korsa Lea, Marusic Zlatko, Dumic-Cule Ivo, Prutki Maja

机构信息

Clinical Department of Diagnostic and Interventional Radiology, University Hospital Centre Zagreb, Kispaticeva 12, 10000 Zagreb, Croatia.

Clinical Department of Pathology and Cytology, University Hospital Centre Zagreb, Kispaticeva 12, 10000 Zagreb, Croatia.

出版信息

Diagnostics (Basel). 2023 Feb 12;13(4):694. doi: 10.3390/diagnostics13040694.

DOI:10.3390/diagnostics13040694
PMID:36832182
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9955433/
Abstract

This study aimed to evaluate the performance of multiparametric breast magnetic resonance imaging (mpMRI) for predicting response to neoadjuvant chemotherapy (NAC) in patients with luminal B subtype breast cancer. The prospective study included thirty-five patients treated with NAC for both early and locally advanced breast cancer of the luminal B subtype at the University Hospital Centre Zagreb between January 2015 and December 2018. All patients underwent breast mpMRI before and after two cycles of NAC. Evaluation of mpMRI examinations included analysis of both morphological (shape, margins, and pattern of enhancement) and kinetic characteristics (initial signal increase and post-initial behavior of the time-signal intensity curve), which were additionally interpreted with a Göttingen score (GS). Histopathological analysis of surgical specimens included grading the tumor response based on the residual cancer burden (RCB) grading system and revealed 29 NAC responders (RCB-0 (pCR), I, II) and 6 NAC non-responders (RCB-III). Changes in GS were compared with RCB classes. A lack of GS decrease after the second cycle of NAC is associated with RCB class and non-responders to NAC.

摘要

本研究旨在评估多参数乳腺磁共振成像(mpMRI)对管腔B亚型乳腺癌患者新辅助化疗(NAC)反应的预测性能。这项前瞻性研究纳入了2015年1月至2018年12月期间在萨格勒布大学医院中心接受NAC治疗的35例管腔B亚型早期和局部晚期乳腺癌患者。所有患者在NAC两个周期前后均接受了乳腺mpMRI检查。mpMRI检查的评估包括形态学(形状、边缘和强化模式)和动力学特征(初始信号增加和时间-信号强度曲线的初始后行为)分析,并额外采用哥廷根评分(GS)进行解读。手术标本的组织病理学分析包括根据残余癌负担(RCB)分级系统对肿瘤反应进行分级,结果显示29例NAC反应者(RCB-0(pCR)、I、II)和6例NAC无反应者(RCB-III)。将GS的变化与RCB类别进行比较。NAC第二个周期后GS缺乏下降与RCB类别和NAC无反应者相关。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/473a/9955433/a7dd2b292385/diagnostics-13-00694-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/473a/9955433/a7dd2b292385/diagnostics-13-00694-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/473a/9955433/a7dd2b292385/diagnostics-13-00694-g001.jpg

相似文献

1
Early Assessment of Neoadjuvant Chemotherapy Response Using Multiparametric Magnetic Resonance Imaging in Luminal B-like Subtype of Breast Cancer Patients: A Single-Center Prospective Study.使用多参数磁共振成像对管腔B样亚型乳腺癌患者新辅助化疗反应进行早期评估:一项单中心前瞻性研究
Diagnostics (Basel). 2023 Feb 12;13(4):694. doi: 10.3390/diagnostics13040694.
2
Impact of Machine Learning With Multiparametric Magnetic Resonance Imaging of the Breast for Early Prediction of Response to Neoadjuvant Chemotherapy and Survival Outcomes in Breast Cancer Patients.机器学习联合乳腺多参数磁共振成像对乳腺癌新辅助化疗早期疗效及生存预后评估的影响。
Invest Radiol. 2019 Feb;54(2):110-117. doi: 10.1097/RLI.0000000000000518.
3
MRI Radiomics for Assessment of Molecular Subtype, Pathological Complete Response, and Residual Cancer Burden in Breast Cancer Patients Treated With Neoadjuvant Chemotherapy.MRI 放射组学在评估新辅助化疗治疗的乳腺癌患者的分子亚型、病理完全缓解和残留癌负荷中的应用。
Acad Radiol. 2022 Jan;29 Suppl 1(Suppl 1):S145-S154. doi: 10.1016/j.acra.2020.10.020. Epub 2020 Nov 5.
4
Prospective Evaluation of Ultrafast Breast MRI for Predicting Pathologic Response after Neoadjuvant Therapies.前瞻性评估超快速乳腺 MRI 预测新辅助治疗后病理反应。
Radiology. 2022 Dec;305(3):565-574. doi: 10.1148/radiol.220389. Epub 2022 Jul 26.
5
99mTc-sestamibi using a direct conversion molecular breast imaging system to assess tumor response to neoadjuvant chemotherapy in women with locally advanced breast cancer.应用 99mTc- sestamibi 直接转换型分子乳腺成像系统评估局部晚期乳腺癌患者新辅助化疗的肿瘤反应。
Clin Nucl Med. 2013 Dec;38(12):949-56. doi: 10.1097/RLU.0000000000000248.
6
Near-Infrared Spectral Tomography for Predicting Residual Cancer Burden during Early-Stage Neoadjuvant Chemotherapy for Breast Cancer.近红外光谱断层成像预测早期新辅助化疗乳腺癌的残余肿瘤负荷。
Clin Cancer Res. 2023 Dec 1;29(23):4822-4829. doi: 10.1158/1078-0432.CCR-23-1593.
7
Predictive value of PET-CT for pathological response in stages II and III breast cancer patients following neoadjuvant chemotherapy with docetaxel.多西他赛新辅助化疗后PET-CT对II期和III期乳腺癌患者病理反应的预测价值
Rev Esp Med Nucl Imagen Mol. 2014 Jan-Feb;33(1):14-21. doi: 10.1016/j.remn.2013.04.008. Epub 2013 Jul 1.
8
Diffusion-weighted MR imaging of locally advanced breast carcinoma: the optimal time window of predicting the early response to neoadjuvant chemotherapy.局部进展期乳腺癌弥散加权 MR 成像:预测新辅助化疗早期疗效的最佳时间窗。
Cancer Imaging. 2018 Oct 29;18(1):38. doi: 10.1186/s40644-018-0173-5.
9
Selection of neoadjuvant treatment based on the 21-GENE test results in luminal breast cancer.基于 21 基因检测结果选择新辅助治疗在 luminal 型乳腺癌中的应用。
Breast. 2021 Apr;56:35-41. doi: 10.1016/j.breast.2021.01.001. Epub 2021 Jan 15.
10
Prediction of survival after neoadjuvant chemotherapy for breast cancer by evaluation of tumor-infiltrating lymphocytes and residual cancer burden.通过评估肿瘤浸润淋巴细胞和残余癌负荷预测乳腺癌新辅助化疗后的生存。
BMC Cancer. 2017 Dec 28;17(1):888. doi: 10.1186/s12885-017-3927-8.

引用本文的文献

1
Development of a multiparametric model for predicting the response to neoadjuvant chemotherapy in breast cancer.用于预测乳腺癌新辅助化疗反应的多参数模型的开发。
Transl Cancer Res. 2024 Feb 29;13(2):558-568. doi: 10.21037/tcr-23-770. Epub 2024 Feb 22.

本文引用的文献

1
Utility of synthetic MRI in predicting pathological complete response of various breast cancer subtypes prior to neoadjuvant chemotherapy.合成 MRI 在新辅助化疗前预测各种乳腺癌亚型病理完全缓解的效用。
Clin Radiol. 2022 Nov;77(11):855-863. doi: 10.1016/j.crad.2022.06.019. Epub 2022 Aug 30.
2
Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients.新辅助化疗后残余肿瘤负担与乳腺癌长期生存结局:5161 例患者的多中心汇总分析。
Lancet Oncol. 2022 Jan;23(1):149-160. doi: 10.1016/S1470-2045(21)00589-1. Epub 2021 Dec 11.
3
Neo-Adjuvant Chemotherapy in Luminal, Node Positive Breast Cancer: Characteristics, Treatment and Oncological Outcomes: A Single Center's Experience.
管腔型、淋巴结阳性乳腺癌的新辅助化疗:特征、治疗及肿瘤学结局:单中心经验
Eur J Breast Health. 2021 Oct 4;17(4):356-362. doi: 10.4274/ejbh.galenos.2021.2021-4-8. eCollection 2021 Oct.
4
Radiomics of MRI for the Prediction of the Pathological Response to Neoadjuvant Chemotherapy in Breast Cancer Patients: A Single Referral Centre Analysis.乳腺癌患者新辅助化疗病理反应预测的MRI影像组学:单转诊中心分析
Cancers (Basel). 2021 Aug 25;13(17):4271. doi: 10.3390/cancers13174271.
5
Breast MRI for Evaluation of Response to Neoadjuvant Therapy.乳腺磁共振成像在新辅助治疗反应评估中的应用。
Radiographics. 2021 May-Jun;41(3):665-679. doi: 10.1148/rg.2021200134.
6
Response Predictivity to Neoadjuvant Therapies in Breast Cancer: A Qualitative Analysis of Background Parenchymal Enhancement in DCE-MRI.乳腺癌新辅助治疗的反应预测性:动态对比增强磁共振成像中背景实质强化的定性分析
J Pers Med. 2021 Apr 1;11(4):256. doi: 10.3390/jpm11040256.
7
Determination of breast cancer prognosis after neoadjuvant chemotherapy: comparison of Residual Cancer Burden (RCB) and Neo-Bioscore.新辅助化疗后乳腺癌预后的测定:残余肿瘤负担(RCB)与Neo-Bioscore 的比较。
Br J Cancer. 2021 Apr;124(8):1421-1427. doi: 10.1038/s41416-020-01251-3. Epub 2021 Feb 9.
8
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.《全球癌症统计数据 2020:全球 185 个国家和地区 36 种癌症的发病率和死亡率估计》。
CA Cancer J Clin. 2021 May;71(3):209-249. doi: 10.3322/caac.21660. Epub 2021 Feb 4.
9
Evaluation of the Efficacy of Neoadjuvant Chemotherapy for Breast Cancer.乳腺癌新辅助化疗疗效评价。
Drug Des Devel Ther. 2020 Jun 18;14:2423-2433. doi: 10.2147/DDDT.S253961. eCollection 2020.
10
Prognostic value of the Residual Cancer Burden index according to breast cancer subtype: Validation on a cohort of BC patients treated by neoadjuvant chemotherapy.根据乳腺癌亚型评估残余肿瘤负担指数的预后价值:对接受新辅助化疗的乳腺癌患者队列的验证。
PLoS One. 2020 Jun 24;15(6):e0234191. doi: 10.1371/journal.pone.0234191. eCollection 2020.